G.E. Coates -
November 30, 2010
Stainless steel 316L (S31603) has traditionally been the workhorse for bio-pharmaceutical production equipment and is likely to remain the dominant alloy in this industry. However, changes in regulatory and performance requirements during the past 15 years have led to the increasing use of more corrosion-resistant
nickel-containing alloys for process equipment.
The super-austenitic stainless steels, commonly referred to as the 6% molybdenum family (for example UNS N08367 or S31254) and the nickel base alloys of the nickel-chromium-molybdenum “C” family (e.g. UNS N10276 or N06022) are now the most common high-performance alloys used in the bio-pharmaceutical manufacturing industry.